BCLI Form 25 Filed With SEC Notifying Nasdaq Removal

Rhea-AI Filing Summary

Nasdaq filed a Form 25 to remove the class of common stock of BrainStorm Cell Therapeutics, Inc. ("BCLI") from listing and/or registration under Section 12(b) of the Exchange Act. The filing identifies the Exchange as Nasdaq Stock Market LLC and lists the issuer's address and telephone number. The form references the regulatory provisions for withdrawal and states Nasdaq certifies it has reasonable grounds to file the Form 25 and that the required compliance steps have been followed.

The document does not disclose which specific rule provision was selected, the effective delisting date, the reason for removal, or whether the withdrawal is voluntary or initiated by the Exchange.

Positive

• Exchange compliance statement indicates Nasdaq followed its internal delisting/withdrawal procedures

Negative

• No effective date or timeline for removal is provided in the filing
• No stated reason for the removal (voluntary vs. Exchange‑initiated) is included

Insights

Corporate Governance Analyst

TL;DR: This filing is a formal notice that the issuer's Nasdaq listing will be removed, but it lacks details on timing or cause.

The Form 25 is a procedural filing that notifies the SEC the Exchange is removing the class of securities for BrainStorm Cell Therapeutics, Inc. It confirms Nasdaq believes it has grounds and has followed its internal rules for delisting or withdrawal.

Key dependencies are the missing items: an effective delisting date and whether the withdrawal is voluntary or Exchange‑initiated. Investors should note this notice alone does not explain implications for trading or registration status without the effective date or accompanying disclosures.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36641

Issuer:	BRAINSTORM CELL THERAPEUTICS INC.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	605 Third Avenue, 34th Floor
	New York	NEW YORK	10158
Telephone number:					(972) 39236384

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-10-09	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filed for BrainStorm Cell Therapeutics (BCLI) mean?

The Form 25 notifies the SEC that Nasdaq intends to remove BCLI's class of securities from listing and/or registration under Section 12(b).

Does the filing state when BCLI will be delisted?

No. The document does not provide an effective delisting date or timeline.

Does the filing say why Nasdaq is removing BCLI from the exchange?

No. The filing references compliance with Nasdaq rules but does not disclose the reason for removal or whether it is voluntary.

Is trading of BCLI automatically halted after this filing?

The Form 25 itself is a notice to the SEC and does not by itself state any change to trading status; the filing does not specify trading halts or the effective date.

Who certified the Form 25 filing for Nasdaq?

The filing states Nasdaq Stock Market LLC certified it had reasonable grounds and caused the notification to be signed by an authorized person, but the signature block is blank in the provided content.